Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus
Dyne Therapeutics shares fell 5.5% to $18.50 Friday, with 2.65 million shares traded. The company plans a U.S. accelerated-approval filing for its Duchenne drug in Q2 2026 and aims to start a Phase 3 trial the same quarter. Next earnings are due Feb. 26. Dyne raised $402.5 million in December through a public offering at $18.44 per share.